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Abstract
Background: Mast cells contribute to tissue repair in fibrous tissues by stimulating proliferation of fibroblasts
through the release of tryptase which activates protease-activated receptor-2 (PAR-2). The possibility that a
tryptase/PAR-2 signaling pathway exists in skeletal muscle cell has never been investigated. The aim of this study
was to evaluate whether tryptase can stimulate myoblast proliferation and determine the downstream cascade.
Methods: Proliferation of L6 rat skeletal myoblasts stimulated with PAR-2 agonists (tryptase, trypsin and SLIGKV)
was assessed. The specificity of the tryptase effect was evaluated with a specific inhibitor, APC-366. Western blot
analyses were used to evaluate the expression and functionality of PAR-2 receptor and to assess the expression of
COX-2. COX-2 activity was evaluated with a commercial activity assay kit and by measurement of PGF2a
production. Proliferation assays were also performed in presence of different prostaglandins (PGs).
Results: Tryptase increased L6 myoblast proliferation by 35% above control group and this effect was completely
inhibited by APC-366. We confirmed the expression of PAR-2 receptor in vivo in skeletal muscle cells and in satellite
cells and in vitro in L6 cells, where PAR-2 was found to be functional. Trypsin and SLIGKV increased L6 cells
proliferation by 76% and 26% above control, respectively. COX-2 activity was increased following stimulation with
PAR-2 agonist but its expression remained unchanged. Inhibition of COX-2 activity by NS-398 abolished the
stimulation of cell proliferation induced by tryptase and trypsin. Finally, 15-deoxy-Δ-12,14-prostaglandin J2 (15Δ-PGJ2),
a product of COX-2-derived prostaglandin D2, stimulated myoblast proliferation, but not PGE2 and PGF2a.
Conclusions: Taken together, our data show that tryptase can stimulate myoblast proliferation and this effect is
part of a signaling cascade dependent on PAR-2 activation and on the downstream activation of COX-2.
Background
Injuries to the musculoskeletal system, such as muscle
damage resulting from extensive and unaccustomed exer-
cise, trauma, dystrophies, ischemia and toxin exposition,
have important functional impacts and therefore very sig-
nificant consequences for daily activities. The same can be
said for the sarcopenia observed in the elderly and the
cachexia typically associated with chronic systemic dis-
eases. Although our general understanding of muscle
damage and regeneration has progressed significantly, the
exact role of various signals and cells implicated in the
process is still unclear in skeletal muscle.
Following muscle damage, there is an orchestrated
recruitment of inflammatory cells, which produce pro-
and/or anti-inflammatory signals leading initially to the
removal of the damaged tissue and subsequently to the
resolution of inflammation and tissue repair [1-5]. The key
steps between inflammation and muscle healing include
the resolution of inflammation and activation of myo-
blasts, which are present as quiescent muscle precursor
cells in the form of satellite cells and stem cells in adult
myofibers. Activated myoblasts migrate to the site of
injury, proliferate, differentiate and fuse into myotubes to
form new myofibers, eventually leading to restoration of
form and function of the damaged muscle. Macrophages,
mast cells, endothelial cells, fibroblasts and muscle fibers
themselves can produce growth and transcription factors
that influence myoblasts during muscle regeneration.
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Indeed, prostaglandins (PGs) and several growth factors
such as fibroblast growth factors (FGFs), insulin-like
growth factor-1 (IGF-1), transforming growth factor beta
(TGF-b), epidermal growth factor (EGF), stem cell factor
(SCF), and hepatocyte growth factor (HGF) have been
identified as potent mediators of myogenesis [6-12].
However, the regulatory processes controlling early myo-
blast activation and subsequent proliferation remain only
partially understood in skeletal muscle.
Mast cells are derived from bone marrow and their role
has long been considered to be restricted to host defense
and allergic reactions. However, it is now well documen-
ted that they can also modulate inflammation onset and
resolution and also the repair phase [1,13-15]. Increase in
the density and the proportion of degranulated mast cells
has been observed in skeletal muscle following various
types of injury [1,16,17]. In models of bupivacaine-
induced muscle injury and unloading-reloading muscle
damage, mast cell stabilization caused a reduced neutro-
phil recruitment and a subsequent increase in the density
of pro-inflammatory macrophages, confirming the impli-
cation of mast cells in modulating leukocyte infiltration
[1,16]. While several studies have looked at the role of
mast cells in the inflammatory period, their potential
action on the myogenic process has been less
investigated.
It is known that mast cells can contribute to tissue
repair and sometimes fibrosis by activating proliferation of
epithelial [18] and smooth muscle cells [19] as well as
fibroblasts [20], through the release of tryptase, a serine
protease [21]. The tryptase-initiated signaling cascade sup-
porting this proliferative response has been elucidated in
fibroblasts [22,23]. These studies have shown that tryptase
modulates the proliferation of these cells through the clea-
vage of protease-activated receptor-2 (PAR-2) and a subse-
quent increase in COX-2 expression, a finding adding
further importance to the role of COX-2 as an important
actor for myogenesis in situation of skeletal muscle repair.
There is now a long list of studies showing that COX-2
inhibition can impair skeletal muscle hypertrophy [24] and
healing [25] processes and that COX-2 regulates growth
of atrophied muscles [26] and early stages of skeletal mus-
cle regeneration [27]. PAR-2 is a G-protein-coupled recep-
tor whose activation requires the cleavage of the
extracellular amino terminus of the receptor. PAR-2
receptor can respond to its known natural agonists such
as tryptase and trypsin and also to synthetic agonists like
SLIGKV. Whereas tryptase is specific to PAR-2 receptor,
trypsin can also cleave and activate PAR-1 and -4 recep-
tors. Data from one study suggest that synthetic PAR-2
agonists influence the proliferation of primary rodent neo-
natal myoblasts [28], but the effect of natural agonists and
the mechanism underlying this phenomenon have not
been documented and remain unknown.
Our objective was thus to document the existence of
such mechanism in skeletal muscle cells. More specifi-
cally, we aimed to: 1) determine whether tryptase, via
PAR-2 activation, stimulates L6 myoblast proliferation in
vitro and 2) identify elements of the signaling cascade
downstream of PAR-2. Our working hypothesis was that
tryptase stimulates myoblast proliferation via cleavage of
PAR-2 receptor and subsequent activation of COX-2.
Our results confirmed the expression of PAR-2 receptor
in L6 myoblasts and in satellite cells of mature rat skele-
tal muscle. In addition, we showed that activation of
PAR-2 receptor leads to stimulation of L6 myoblast pro-
liferation and that this effect is dependent on COX-2
activity.
Methods
Animals
Female Wistar rats weighing 125-150 g were used to
determine the presence of PAR-2 in mature skeletal mus-
cle. The treatment and care of these animals were
approved by the Laval University Research Center Animal
Care and Use Committee based on the guidelines of the
Canadian Council on Animal Care.
Muscle homogenization of rat extensor digitorum longus
(EDL) for PAR-2 probing
EDL muscles were homogenized at 4°C in lysis buffer con-
taining 20 mM Tris, pH 7.5, 140 mM NaCl, 1 mM MgCl2,
1 mM CaCl2, 10% glycerol, 1% Igepal, 2 mM Na3VO4, 8.3
mM NaF, 0.2 mM PMSF and a cocktail of protease inhibi-
tors P3840 from Sigma-Aldrich (St-Louis (MO), USA)
using using a Polytron. Protein content was determined
using bicinchoninic acid (BCA) protein assay reagent
(Thermo Fisher Scientific, Rockforf (IL), USA).
Cell culture
Subconfluent cultures of immortalized L6 rat skeletal
myoblasts (ATCC, Manassas (VA), USA) were maintained
in a-Mimimum Essential Medium (a-MEM) (Gibco,
Carlsbad (CA), USA) supplemented with 10% fetal bovine
serum (FBS) (HyClone, Logan (UT), USA).
Proliferation assay
For measurement of proliferation rate, cells were seeded
onto 96-well plate at a density of 3,000 cells/well in 65 μL
of a-MEM containing 1% FBS and treated with or without
tryptase (Sigma-Aldrich; St-Louis (MO), USA), trypsin
(Sigma-Aldrich), PAR-2 synthetic activating peptide
SLIGKV (Bachem Americas; Torrance (CA), USA), or
prostaglandins PGF2a, PGE2 or 15Δ-PGJ2 (Cayman
Chemical; Ann Arbor (MI), USA), at various doses for
48 h. When testing tryptase inhibition, tryptase was pre-
incubated with a specific tryptase inhibitor, APC-366
(kind gift from American Peptides; Vista, (CA), USA), for
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30 min at 37°C before addition to cells while COX-2 inhi-
bition was tested by pre-incubation with a specific COX-2
inhibitor, NS-398, under the same conditions. The media
was renewed after the first 24 h of incubation. In all
experiments, the number of viable cells at the end of the
experiment was determined by the use of CellTiter 96
Aqueous One Solution cell proliferation assay (Promega,
Madison (WI), USA) according to the protocol proposed
by the manufacturer.
Western Blot
For analysis of COX-2 protein expression, adherent L6
cells were stimulated by tryptase (4 mU/ml) for 60 min or
lipopolysaccharide (LPS) (10 μg/ml) (Sigma-Aldrich, St-
Louis (MO), USA) for 3 h. For phospho-ERK1/2 protein
expression, cells were deprived of serum for 4 h before
being stimulated by tryptase (4 mU/ml) pre-incubated or
not for 30 min at 37 °C with APC-366 (300 μM) or with
NS-398 (100 μM) for periods ranging from 10 to 120 min.
Cells were lysed in the lysis buffer previously described
and protein content was determined by BCA protein assay
reagent. Immunoblots were performed as described [29]
by using primary antibodies PAR-2 (dilution 1:500) (Santa
Cruz Biotechnology, Santa Cruz (CA), USA), COX-2 (dilu-
tion 1: 1,000) (Santa Cruz Biotechnology, Santa Cruz (CA),
USA), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204),
p44/p42 MAPK (ERK1/2) (137F5) (dilution 1:1,000) (Cell
Signaling Technology, Danvers (MA), USA) or GAPDH
(1:1,000) (Santa Cruz Biotechnology, Santa Cruz (CA),
USA) and their secondary antibodies which are anti-rabbit
HRP conjugated (dilution 1:10,000) (Amersham, Buckin-
ghamshire, England) for PAR-2, p44/42 MAPK and
GAPDH, anti-goat HRP conjugated (dilution 1:10,000)
(Santa Cruz Biotechnology) for COX-2 or anti-mouse
HRP conjugated (dilution 1:10,000) (Santa Cruz Biotech-
nology) for phospho-p44/42 MAPK.
Reverse transcription and quantitative PCR (Q-PCR)
analysis
For analysis of COX-2 gene expression, L6 cells were
seeded in a-MEM 1% for 3 h before being stimulated by
tryptase (4 mU/ml) for 10 to 120 min. RNA extraction
was performed using RNeasy mini kit (Qiagen, Hilden,
Germany) following the manufacturer protocol. 4 μg of
total RNA was used for cDNA synthesis using Superscript
II reverse transcription kit (Invitrogen Corporation, Carls-
bad (CA), USA) in recommended conditions, using 500 ng
of random hexamers (Roche, Nonnenwald, Germany). Pri-
mers used to amplify cDNA were designed using the free
software Primer 3 (by Steve Rozen and Helen J, Skaletsky)
available online at http://frodo.wi.mit.edu/primer3/. For
COX-2, they were S: 5’-CTGAGGGGTTACCACTTCCA-
3’ and AS: 5’-TGAGCAAGTCCGTGTTCAAG-3’ and for
the house-keeping gene GAPDH, they were S: 5’-
AAACCCATCACCATCTTCCA-3’ and AS: 5’-GTGGTT
CACACCCATCACAA-3’. The sequences were further
analyzed with the software Amplify 3X (http://engels.
genetics.wisc.edu/amplify/index.html) and synthesized at
our institution. Q-PCR was performed by using a 36-well
Rotor-Gene-3000 thermal cycler (Corbett Research, Mor-
tlake, New South Wales, Australia) and results were ana-
lyzed with Rotor Gene version 6.0.27 software. cDNA
(4 μl) from each sample were amplified by gene-specific
primers described above (100 nM of each primer) in a 20
μl reaction containing 500 mM dNTP (Roche, Nonnen-
wald, Germany), 3 mM MgCl2 (Sigma-Aldrich, St-Louis
(MO), USA), SYBR® Green (1/30,000 dilution) (Invitrogen
Corporation, Carlsbad (CA), USA), 5% DMSO (Sigma-
Aldrich, St-Louis (MO), USA) and 1 U Taq polymerase
(Roche, Nonnenwald, Germany). Thermal profile was:
95°C (15 s), 63°C (20 s), 72°C (25 s); 35 cycles. Fluores-
cence produced by SYBR® Green was measured at the
end of the extension step of each cycle. At the end of the
35 cycles of amplification, the Melt® Procedure was per-
formed to determine the specificity of the amplification.
The fold increase of gene expression of COX-2 above
GAPDH was evaluated by 2ΔΔCT relative quantification
method described by Dussault et al. (2006) [30], where CT
represents the cycle number where the fluorescence inten-
sity reaches a threshold value in a PCR reaction expressed
in the exponential phase.
Immunohistochemistry
Transverse sections (10 μm thick) were obtained in the
mid-belly section of the EDL muscle. Sections were
adhered to positive charged microscope slides for immu-
nostaining of PAR-2 and PAX-7 as previously described
[31]. Briefly, sections were incubated with or without
(negative control) primary anti-PAR-2 antibody (1:200)
(Santa Cruz Biotechnology, Santa Cruz (CA), USA) or
anti-PAX-7 antibody (1:100) overnight at 4°C and followed
by a 1 h incubation with biotinylated anti-rabbit IgG and
biotinylated anti-mouse IgG secondary antibodies (1:200),
respectively. The monoclonal antibody PAX-7 developed
by Kawakami, A. was obtained from the Developmental
Studies Hybridoma Bank developed under the auspices of
the NICHD and maintained by The University of Iowa,
Department of Biology, Iowa City, IA 52242.
Measurement of COX activity
COX-2 activity was assessed directly by the use of a com-
mercial COX activity assay kit (Cayman Chemical),
allowing measurement of total COX activity and of the
relative contribution of the two isoforms (COX-1 and -2)
when using the selective COX-1 inhibitor SC-560. Briefly,
cells were seeded in a-MEM supplemented with 10% FBS
until reaching 80-90% confluence and then incubated for
2 h with or without trypsin (200 nM) for 30 min at 37°C
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before performing the test according to the procedure
proposed by the manufacturer. To further validate these
measurements, COX activity was also assessed indirectly
via measurement of PGF2a production. Cells were seeded
in a-MEM supplemented with 1% FBS until reaching
80-90% confluence. Cells were then incubated for 12 h
with trypsin (200 nM) or tryptase (2 mU/ml), or pre-
incubated with indomethacin (10 μM) (Sigma) or NS-398
(100 μM) for 30 min at 37°C before the addition of PAR-
2 agonist. Production of PGF2a was assayed by enzyme
immunoassay using a custom-made competitive ELISA
as described previously [32].
Statistical analysis
Data are presented as means ± s.e.m. Data were ana-
lyzed using Tukey-Kramer HSD multiple-comparison
test when significant F ratios were obtained following
two-way ANOVAs. P < 0.05 was considered to be statis-
tically significant.
Results
Expression and functionality of PAR-2 receptor
The expression of PAR-2 receptor was detectable in L6
cells and in rat skeletal muscle (EDL) (Figure 1A). The
assessment of PAR-2 distribution by immunohistochemis-
try showed that PAR-2 is expressed at the membrane level
of muscle fibers (Figure 1B, black arrows) and in satellite
cells, which were identified by PAX-7 staining (Figure 1C
and 1D). Specificity of PAR-2 staining was validated by the
intense staining observed around blood vessel since
endothelial cells are known to express PAR-2 receptor
[33] (Figure 1B, white arrow). In L6 cells stimulated with
tryptase, the proportion of phosphorylated ERK1/2, a
downstream indicator of PAR-2 activation [23,33],
increased significantly compared to untreated cells
whereas no significant response was seen when tryptase
was pre-incubated with its specific inhibitor, APC-366
(Figure 2A and 2B). Pre-incubation with the COX-2 speci-
fic inhibitor NS-398 did not influence tryptase-induced
phosphorylation of ERK1/2 (Figure 2A and 2B). These
results confirmed that PAR-2: 1) is present and functional
in L6 cells, 2) is expressed in satellite cells of mature skele-
tal muscle, and 3) can be activated by tryptase.
Effect of tryptase, trypsin and activating peptide on L6
myoblast proliferation
We next verified if PAR-2 activation by natural and syn-
thetic agonists could stimulate cell proliferation. Tryptase
increased proliferation of L6 cells by 35% above control at
a concentration of 2 mU/ml (Figure 3A). Pre-incubation
of tryptase with APC-366 caused a dose-dependent inhibi-
tion of the effect of tryptase on L6 cell proliferation (Fig-
ure 3B). L6 cell viability was not affected by APC-366 at
the maximal concentration used (Figure 3C). To further
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Figure 1 PAR-2 receptor expression in L6 myoblasts, in
myofibers and in satellite cells of skeletal muscle. A) Expression
of PAR-2 receptor in L6 myoblasts and skeletal muscle (EDL) by
western blot (representative sample of 4 separate experiments). B)
Detection of PAR-2 protein by immunohistochemistry on EDL
muscle myofibers (black arrows) and blood vessel (white arrow). C)
and D) Immunohistochemistry performed on two consecutive
sections showed that satellite cells identified by PAX-7 staining (C)
also expressed PAR-2 receptor (D). The numbered cells 1 to 6
served to the localization of satellite cell on consecutives sections. E)
Negative control of an immunohistochemistry performed without
primary antibody PAR-2 or PAX-7. Bar = 50 μm.
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confirm the implication of PAR-2 in the cascade modulat-
ing L6 myoblast proliferation, trypsin and the PAR-2 acti-
vating peptide SLIGKV were used. Both were found to
stimulate L6 cell proliferation in a dose-dependent manner
(Figure 3D, 3E). More precisely, trypsin increased prolif-
eration by 76% while SLIGKV stimulated proliferation to a
lower extent (26%). These results confirm that activation
of PAR-2 receptor stimulates L6 myoblast proliferation.
Implication of PAR-2 and COX-2 in L6 myoblast
proliferation
Since it has been demonstrated in fibroblasts that COX-2
is part of the signaling cascade leading to the stimulation
of proliferation following PAR-2 activation, we investi-
gated its putative role in the modulation of L6 myoblast
proliferation. COX-2 was found to be constitutively
expressed in L6 myoblasts and contrary to what was seen
in fibroblasts, we were unable to detect any modulation of
its expression following tryptase stimulation (Figure 4A).
The same conclusion was reached by using Q-PCR to look
at COX-2 mRNA level (data not shown). However, these
results did not exclude the possibility of a modulation of
the activity of COX-2. Measurement of COX-2 activity
revealed a 7.1 fold increase in L6 cells stimulated with
trypsin, whereas COX-1 activity was not increased signifi-
cantly (Figure 4B). To further validate this finding, we
looked at PGF2a production in L6 cells following PAR-2
activation and found that tryptase and trypsin led respec-
tively to a 1.6 and 5.4 fold stimulation above control (Fig-
ure 4C), whereas the COX inhibitors NS-398 (COX-2
specific) and indomethacin (COX-1 and -2) abolished this
effect to the same extent (data not shown). As could be
predicted based on these findings, inhibiting COX-2 activ-
ity with NS-398 very significantly blunted the effect of
tryptase and trypsin on cell proliferation (Figure 4D), an
effect that could not be explained by a toxic effect of NS-
398 since it did not impact on cell viability at the concen-
trations used (Figure 3C).
The modulation of COX-2 activity following PAR-2
activation led us to test the influence of various PGs on
L6 cell proliferation. Exogenous PGE2 and PGF2a did not
have any effect on cell proliferation, but 15Δ-PGJ2, a final
product of COX-2-derived PGD2, stimulated L6 cell pro-
liferation in a dose-dependent manner (Figure 4E). Taken
together, these results suggest that modulation of COX-2
activity, and not its expression, is an intricate part of the
cascade modulating L6 myoblast proliferation following
PAR-2 activation and that 15Δ-PGJ2 could be implicated.
Discussion
Mast cells have been identified as an important actor in
the inflammatory process following injury and allergic
reactions. However, there is also strong evidence sug-
gesting an implication of mast cells in tissue regenera-
tion through stimulation of cell proliferation. For
instance, mast cell tryptase and PAR-2 receptor signal-
ing pathway can stimulate proliferation in some cell
types and is even linked to uncontrolled cell prolifera-
tion in various diseases such as mastocytosis [34], fibro-
sis [22] and asthma [35]. While several observations
point for a role of mast cells in processes governing
inflammation and regeneration of skeletal muscle regen-
eration, the relevance of this signaling cascade in this
tissue has yet to be addressed.
PAR-2 expression and activation by various agonists
Although the presence of PAR-2 receptors in skeletal
muscle cells was previously observed in primary rodent
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neonatal myoblasts [28], we show here that immortalized
L6 cells and satellite cells of rat mature skeletal muscle
also express PAR-2 receptor, which is the only known
receptor for tryptase [36]. The functionality of the recep-
tor was also confirmed by the increased phospho-ERK1/2
content following tryptase-induced PAR-2 activation.
Phospho-ERK1/2 is considered as a surrogate marker of
the activation of PAR-2 [33] and is associated with tryp-
tase-induced PAR-2 activation in human fibroblasts [22].
Tryptase inhibitor strongly annihilated the increase in
phospho-ERK1/2 and the proliferative effect supporting
the specificity of PAR-2 activation by tryptase. Lastly, the
failure of NS-398 to modulate the phosphorylation of
ERK1/2 following tryptase-induced PAR-2 activation sug-
gests that this step is downstream of PAR-2 activation
and upstream of COX-2 activation. These observations
are in line with data from Frungieri et al. (2005) who
demonstrated in human fibroblasts that the initial events
of the tryptase/PAR-2 signaling pathway leading to cell
proliferation rely on the activation of ERK1/2 [23]. We
conclude that a functional PAR-2 receptor is expressed
in L6 cells and that it can be stimulated by its two natural
agonists and this leads to activation of ERK1-2.
Trypsin, a natural activator of PAR-2 [28], has been
shown to mimic the proliferative effect of tryptase
[37-39]. In our study, trypsin was a more potent stimu-
lator of cell proliferation than tryptase, a finding pre-
viously observed [40]. One possible explanation for this
difference is that trypsin is a PAR-1, -2 and -4 agonist
while tryptase is PAR-2 specific. PAR-1 is expressed in
myoblasts before fusion and PAR-1 agonists are able to
stimulate proliferation of primary myoblasts [41]. As a
result, we believe the response observed with trypsin in
these experiments may have been the summation of
both PAR-1 and -2 stimulations. The PAR-2 synthetic
activating peptide (SLIGKV), on the other hand, induced
a smaller response than tryptase and trypsin on L6 cells.
This lower potency of SLIGKV is likely related to the
inefficient presentation of the soluble peptide to its
receptor binding domain leading to a less efficient sti-
mulation compared to other molecules and/or to a
shorter half-life in cell culture medium [36]. Another
hypothesis to explain the difference between these three
agonists is that PAR signaling can show ‘functional
selectivity’ or ‘biased agonism’, a phenomenon leading to
different signaling responses following activation of the
same receptor by different agonists. Such behavior has
been demonstrated for PAR-2 [42]. This phenomenon
suggests that the effect observed following synthetic
agonist stimulation does not correspond to a physiologi-
cal response and reinforces the novelty of our study
which documents the effect of natural PAR-2 agonists
on skeletal muscle cell proliferation.
PAR-2 activation stimulates L6 myoblast proliferation
through a COX-2 dependent mechanism
In fibroblasts, cells with a very low constitutive expres-
sion of COX-2, activation of PAR-2 stimulates cell pro-
liferation and leads to a very significant increase in the
expression of COX-2 protein [22]. In L6 cells, we found
a substantial constitutive expression of COX-2 protein,
which was not modulated by stimulation of PAR-2 with
tryptase. Constitutive COX-2 expression has also been
reported in primary myoblast cultures and COX-2 activ-
ity was detected at basal level in these cells [26]. Inter-
estingly, we also found that COX-2 is constitutively
expressed in L6 myotubes and C2C12 myoblasts and
myotubes (data not shown). COX-2 thus appears to be
a constitutive component of not only proliferating myo-
blasts but also of differentiating myotubes in these two
cell lines, observations again supporting its importance
in muscle cell physiology.
The present data demonstrate that specific inhibition
of COX-2 activity by NS-398 totally abolished the effect
of tryptase and trypsin on L6 cell proliferation, a finding
consistent with the growing number of papers showing
that COX-2 inhibition can impact on skeletal muscle
hypertrophy [24] and repair [25,27] and primary satellite
cell proliferation [43]. However, in most of these papers,
the outcome measures following COX-2 inhibition were
mainly at the functional level with no attempt at identi-
fying the signaling cascade. In the present study, we
show a functional effect of COX-2 inhibition on cell
proliferation that we were able to link to a signaling cas-
cade. The crucial role of COX-2 in this cascade was
further confirmed by the direct assessment of COX
activity which revealed that a concentration of trypsin
stimulating cell proliferation led to a very significant
increase in COX-2 activity. Because specific COX-2
inhibitor (NS-398) and non-specific COX-1 and -2 inhi-
bitor (indomethacin) induced the same level of inhibi-
tion on PGF2a production and total COX activity, we
conclude that only COX-2 is involved. Overall, these
experiments solidly confirm the implication of COX-2
activity in the signaling cascade. This finding can be
integrated to results showing that COX-2 derived PGs
are important for myogenesis and essential for the regu-
lation of muscle growth in stretch-induced myoblast
proliferation [44] and in skeletal muscle hypertrophy
[24] and regeneration following injury [27] and atrophy
[26]. Pavlath et al. previously demonstrated that the
COX-2 pathway regulates early stages of myofiber
growth during muscle regeneration. They postulated
that attenuated myonuclear addition caused by COX-2
inhibition could explain the impact on growth: since
myonuclear addition depends on satellite cell activation
and proliferation, we propose that the PAR-2 cascade
Duchesne et al. BMC Musculoskeletal Disorders 2011, 12:235
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we depict here is the link between COX-2 activity and
myoblast activation and proliferation.
To further investigate the role of COX-2 activity, we
tested the effect of three PGs on cell proliferation. Our
observations showed that only 15Δ-PGJ2 stimulated L6
cell proliferation while PGF2a and PGE2 were found to be
without effect. Evidence supporting the role of 15Δ-PGJ2
in the resolution phase of inflammation is growing
[45-47]; furthermore, it was shown to stimulate human
fetal foreskin fibroblast proliferation [22]. In our model,
the stimulating effect induced by 15Δ-PGJ2 was very sig-
nificant and further underlines the importance of COX-2
activity. 15Δ-PGJ2 is traditionally known to exert its effect
through PPARg [22] and is considered its natural ligand.
PPARg expression can be detected in whole extracts of
skeletal muscle [48,49], but its specific expression in myo-
blasts has not been reported so far and the consensus is
that it is not expressed in myocytes. However, there is
growing evidence that 15Δ-PGJ2 can have PPARg-inde-
pendent effects. For example, 15Δ-PGJ2 can inhibit TNFa
production by covalent binding of IB kinase, thus keep-
ing the transcription factor NF-B in an inactive state
[46,50]. 15Δ-PGJ2 can also act directly via DP1 receptor to
accomplish its anti-inflammatory effects [47]. We must
thus conclude that the effect of 15Δ-PGJ2 on myoblast
proliferation is likely PPARg-independent and further
work will be required to identify the target.
Conclusions
In summary, we showed that the PAR-2 agonist tryptase
can modulate L6 myoblast proliferation which involves the
modulation of COX-2 activity and possibly 15Δ-PGJ2 pro-
duction. These data suggest that mast cells, via tryptase
release, could be one of the components in the process
triggering the proliferation of myoblasts, as it is the case
with other cells such as fibroblasts, epithelial cells and
smooth muscle cells. In addition, this study reveals that
the largely reported influence of COX-2 on muscle regen-
eration may be explained, at least in part, by its implica-
tion in this signaling cascade supporting skeletal muscle
cell proliferation. Clinically speaking, these data should be
added to an extensive list of publications showing that
cells classically limited to the inflammatory phase are also
important for the regeneration phase of tissue repair.
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